Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

Johnathan E. Rosenberg, MD
Published: Thursday, May 25, 2017



Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.

The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.
 


Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.

The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x